Updates to the Australian Pharmaceutical Benefits Scheme
22 May 2023
Update
Services Australia has published a release detailing new and amended listings of medications on the Australian Pharmaceutical Benefits Scheme (PBS), effective from 1 May 2023.
Amendments have been made to a range of medications on the PBS, including the following medications:
- Methylphenidate (Ritalin® LA) being amended to allow access for adults with a retrospective diagnosis of ADHD. This includes access to capsules containing methylphenidate hydrochloride 10 mg, 20 mg, 30 mg, 40 mg, 60mg (modified release).
- Naltrexone (Naltrexone GH®) having a reduction in authority level for the treatment of alcohol dependence.
Enquiries regarding new and amended listings can be directed to the PBS at pbs@health.gov.au.
More news & views
19 June 2026
News
Professor Andrew Stripp AM appointed as the RANZCP’s inaugural Independent DirectorThe RANZCP is delighted to announce the appointment of Professor Andrew Stripp AM as the inaugural I...
18 June 2026
Update
Congratulations to the RANZCP Fellows recognised in the 2026 King’s Birthday HonoursThe RANZCP is pleased to announce that six psychiatrists have been recognised in the 2026 King's Bir...
16 June 2026
Update
Psychiatry Interest Forum program at RANZCP 2026 CongressForty PIF medical students and junior doctors were supported to attend the 2026 RANZCP Congress in M...